Coherus Oncology Inc 2026年季度报告

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Coherus Oncology,Inc. (Exact Name of Registrant as Specified in Its Charter) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant (1)hasfiled all reports required to befiled by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was requiredtofile such reports), and (2)has been subject to suchfiling requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large acceleratedfiler, an acceleratedfiler, a non-acceleratedfiler, asmaller reporting company, or an emerging growth company. See the definitions of “large acceleratedfiler,” “acceleratedfiler,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Non-acceleratedfiler☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revisedfinancial accounting standards provided pursuant to Section13(a)of theExchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ As of April 30, 2026, 154,249,900 shares of the registrant’s common stock were outstanding. COHERUS ONCOLOGY,INC.FORM10-Q FOR THE QUARTER ENDED MARCH 31, 2026TABLE OF CONTENTS PageCAUTIONARY NOTEREGARDING FORWARD-LOOKING STATEMENTS3PARTIFINANCIAL INFORMATION7ITEM1Unaudited Condensed Consolidated Financial Statements7Condensed Consolidated Balance Sheets7Condensed Consolidated Statements of Operations and Comprehensive Loss8Condensed Consolidated Statements of Stockholders’ Equity (Deficit)9Condensed Consolidated Statements of Cash Flows10Notesto Condensed Consolidated Financial Statements11ITEM2Management’s Discussion and Analysis of Financial Condition and Results of Operations26ITEM3Quantitative and Qualitative Disclosure About Market Risk34ITEM4Controls and Procedures34PARTIIOTHER INFORMATION35ITEM1.Legal Proceedings35ITEM1A.Risk Factors35ITEM2Unregistered Sales of Equity Securities and Use of Proceeds, and Issuer Purchases of EquitySecurities83ITEM3Defaults Upon Senior Securities83ITEM4Mine Safety Disclosures83ITEM5Other Information83ITEM6.Exhibits84Signatures85 LOQTORZI®, whether or not appearing in large print or with the trademark symbol, is a registeredtrademark of Coherus. Trademarks and trade names of other companies appearing in this QuarterlyReport on Form 10-Q are, to the knowledge of Coherus, the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form10-Q contains forward-looking statements regarding future events andour future results that are subject to the safe harbors created under the Securities Act of 1933, as amended(the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Anystatements contained herein that are not statements of historical facts contained in this Quarterly Report onForm10-Q may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by words such as “aim,” “anticipate,” “assume,” “attempt,” “believe,” “contemplate,”“continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,”“potential,” “seek,” “should,” “strive,” “target,” “will,” “would” and other similar expressions that arepredictions of or indicate future events and future trends, or the negative of these terms or othercomparable terminology. These forward-looking statements include, but are not limited to, statementsabout: ●whether our available cash, cash equivalents and marketable securities, and product sales willbe sufficient to fund our planned expenditures and meet our obligations in the future;●whether we will be able to continue to maintain or increase sales for our product LOQTORZI®(toripalimab-tpzi);●our expectations regarding our ability to develop and commercialize our product candidates;●our ability to maintain regulatory approval for our product and our ability to obtain andmaintain regulatory approval of our product candidates, if and when approved;●our expectations regarding government and third-party payer coverage and reimbursement;●our ability to manufacture our product and product candidates in conformity with regulatoryrequirements and to scale up manufacturing capacity of our product and product candidates forcommercial supply;●our reliance o